OTC Bulletin Board S & P Company Insight for GEOVAX LABS INC
Profile
	Business Summary: GeoVax Labs, Inc., a biotechnology company, focuses on developing vaccines to protect against or to treat diseases caused by human immunodeficiency virus (HIV).   Address   1900 Lake Park Drive, Suite 380   Smyrna , GA 30080   Phone: 678-384-7220   Fax: 678-384-7281   Website: http://www.geovax.com Transfer Agent   American Stock Transfer & Trust Co. Employees:  15 ShareHolders:  1200 Founded:  1987 Domicile:  Delaware
Background
	GeoVax Labs, Inc., a biotechnology company, focuses on developing vaccines to protect against or to treat diseases caused by human immunodeficiency virus (HIV). The company's ongoing research and development programs are focused on the clinical development of its DNA and MVA vaccines for the prevention and/or treatment of HIV/AIDS. It is developing two clinical pathways for its vaccine candidates, as a preventative vaccine to prevent development of AIDS in healthy individuals who are exposed to the HIV virus and as a therapeutic vaccine to prevent development of AIDS in those individuals who have already been infected with the HIV virus. GeoVax Labs' preventative vaccine candidate is in a Phase IIa clinical trial. In addition to its clinical development program for its vaccine candidates, the company is conducting preclinical research on the impact of adding adjuvants (immune system stimulants) to its vaccine components to investigate whether they can improve the effectiveness of its vaccine candidates. GeoVax Labs is based in Smyrna, Georgia. History:  INCORPORATED in Delaware June 17, 2008; and on June 18, 2008, merged its parent, an Illinois corporation of the same name, on a share-for-share basis. Former parent was incorporated in Illinois Apr. 26, 1991, as Dauphin Technology, Inc. On June 14, 1991, it merged Dauphin Technology, Inc., a Utah corporation (Dauphin - Utah); and on Sept. 6, 1991, it merged DT of Illinois, Inc., its wholly owned subsidiary. DT of Illinois, Inc. was incorporated in Illinois June 6, 1988, as Dauphin Technology, Inc. and was acquired by Dauphin - Utah on Apr. 4, 1991. Dauphin - Utah was originally organized in Utah as Sucesso, Inc. on Sept. 8, 1987, and changed its name to Dauphin Technology, Inc. on Apr. 5, 1991. Dauphin Technology, Inc., the Illinois corporation that was later merged, changed its name to DT of Illinois, Inc. on Apr. 23, 1991. September 28, 2006, acquired GeoVax, Inc. through a merger transaction. Following the merger, Common shareholders of GeoVax, Inc. and holders of GeoVax, Inc. Redeemable Convertible Preferred stock received a total of 490,332,103 Common shares of the company. The company changed its name to GeoVax Labs, Inc. on Sept. 28, 2006. GeoVax, Inc., the acquired concern, was incorporated in Georgia June 27, 2001.   Subsidiaries: GeoVax, Inc.     Capital Expenditures, thousand. US Dollars   Year   Amount   2009   270   2008   100   Research and Development Expenditures, thousand. US Dollars   Year   Amount   2009   4,068   2008   3,741
Management
	Management Officers Position  Donald G. Hildebrand Chairman  Robert T. McNally President & Chief Executive Officer  Mark W. Reynolds Secretary, Chief Financial Officer & Chief Accounting Officer  Harriet  Robinson Chief Scientific Officer  James  Carbonara Investor Relations Contact Directors  Steven S. Antebi  David A. Dodd  Donald G. Hildebrand  Dean G. Kollintzas  Robert T. McNally  Harriet  Robinson  John N. Spencer, Jr.  Peter M. Tsolinas
Annual Report
	Annual Report   Income Statement   2009 2008 2007 REVENUES Grant Revenues 3,668,195 2,910,170 237,004 EXPENSES General and Administrative (2,914,845) (2,970,068) (2,784,182) Research and Development (4,068,682) (3,741,489) (1,757,125) Interest Income 31,080 73,200 62,507 Earnings before Taxes (3,284,252) (3,728,187) (4,241,796) TAXES AND OTHER EXPENSES Net Income (Loss) (3,284,252) (3,728,187) (4,241,796) SUPPLEMENTARY INFO Operating Income (Loss) (3,315,332.00) (3,801,387.00) (4,304,303.00) Basic EPS - Continuing Operations Nil (0.01) (0.01) Diluted EPS - Continuing Operations Nil (0.01) (0.01)   Balance Sheet   2009 2008 CURRENT ASSETS Cash and Cash Equivalents 3,515,784 2,191,180 Grant Funds Receivable 320,321 311,368 Prepaid Expenses and Other 44,615 299,286 Total Current Assets 3,880,720 2,801,834 NON CURRENT ASSETS Property and Equipment 344,202 138,847 Licenses 89,695 114,580 Deposits and Other 980 980 Total Assets 4,315,597 3,056,241 CURRENT LIABILITIES Accounts Payable and Accrued Expenses 408,344 176,260 Amounts Payable to Emory University 163,021 170,162 Total Current Liabilities 571,365 346,422 SHAREHOLDERS' EQUITY Common Stock - Par Value 781,628 747,449 Additional Paid in Capital 20,500,450 16,215,970 Deficit Accumulated during the Development Stage (17,537,850) (14,253,600) Total Shareholders Equity 3,744,232 2,709,819 Total Liabilities & Shareholders Equity 4,315,597 3,056,241
Interim Report
	Interim Report      Data Not Available
Pro Forma Report
	Pro Forma Report      Data Not Available
Quarterly Report
	Quarterly Report Information      Quarterly Revenue, US$ Year Quarter Revenue   2010   1 1,340,000   2009   1 710,000   2009   2 750,000   2009   3 1,810,000   2009   4 400,000   2009   Full Year 3,670,000   2008   1 600,000   2008   2 380,000   2008   3 1,320,000   2008   4 610,000   2008   Full Year 2,910,000   2007   1 Nil   2007   2 Nil   2007   3 Nil   2007   4 240,000   2007   Full Year 240,000   2006   1 Nil   2006   2 480,000   2006   3 Nil   2006   4 370,000   2006   Full Year 850,000   2005   1 170,000   2005   2 60,000   2005   3 430,000   2005   4 20,000   2005   Full Year 670,000     Quarterly Net Income, US$ Year Quarter Revenue   2010   1 (690,000)   2009   1 (860,000)   2009   2 (1,350,000)   2009   3 (230,000)   2009   4 (840,000)   2009   Full Year (3,280,000)   2008   1 (680,000)   2008   2 (1,280,000)   2008   3 (720,000)   2008   4 (1,040,000)   2008   Full Year (3,730,000)   2007   Full Year (4,240,000)   2006   Full Year (580,000)   2005   Full Year (1,610,000)     Quarterly EPS, US$ Year Quarter Revenue   2010   1 (.04)   2009   1 (.06)   2009   2 Nil   2009   3 Nil   2009   4 Nil   2009   Full Year Nil   2008   1 Nil   2008   2 Nil   2008   3 Nil   2008   4 Nil   2008   Full Year (.50)   2007   1 Nil   2007   2 Nil   2007   3 Nil   2007   4 (.50)   2007   Full Year (.50)   2006   1 Nil   2006   2 Nil   2006   3 Nil   2006   4 Nil   2006   Full Year Nil   2005   1 Nil   2005   2 Nil   2005   3 Nil   2005   4 (.50)   2005   Full Year (.50)
Stock Data
	Capitalization as of 03/31/2010:     Authorized Shares Outstanding Shares Common $0.001 par 40,000,000 15,652,814so1 Preferred $0.001 par 10,000,000 None   LONG TERM DEBT: None.   Common $0.001 par   Stockholders:  05/20/2010, 1200. PRINCIPAL STOCKHOLDERS: May 21, 2010, Emory University owned or controlled 29.5% of the Common, and Welch & Forbes LLC 10.1%.   Transfer Agent:  American Stock Transfer & Trust Co.   New York , NY   OTC Bulletin Board( Primary): GOVX   Exchange Year High Low OTC Bulletin Board 2009 0.3800 0.0900 OTC Bulletin Board 2008 0.2900 0.0900 OTC Bulletin Board 2007 0.5000 0.1610 OTC Bulletin Board 2006 1.1600 0.1850   DIVIDENDS: Common $0.001 par: No cash. Common reverse split 1-for-50, Apr. 28, 2010.       so1Adjtd. for 1-for-50 reverse split Apr. 28, 2010.